Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- Astellas to End License Agreement with US Venture Company for AD Treatments
October 20, 2014
- AMO Japan Appoints Shoko Suzuki of Coca-Cola Japan as New President
October 20, 2014
- Takeda, euglena Strike Comprehensive Collaboration Deal for Euglena-Containing Product Development
October 20, 2014
- Bayer AG Aims to Achieve Japan Sales of 300 Billion Yen by 2017
October 17, 2014
- Bayer HealthCare Signs Two-Year Collaborative Search Activity Agreement with Kyoto Univ.
October 17, 2014
- FDA Gives Priority Review Status to Lenvatinib, Rufinamide: Eisai
October 17, 2014
- Pfizer Japan Voluntarily Recalls Torisel Due to Microparticles in Diluent
October 17, 2014
- EPS to Take Full Control of EP-Mint in January
October 16, 2014
- Mochida Hooks Up with LG Life Sciences on Adalimumab Biosimilar
October 16, 2014
- Daiichi Sankyo Launches Tender Offer for US Biotech Ambit
October 16, 2014
- FDA OKs World’s 1st Oral Combination Drug for CINV: Helsinn, Eisai
October 16, 2014
- Astellas, Harvard Conduct Joint Research for Retinitis Pigmentosa
October 16, 2014
- Kyorin Licenses Uritos to R-Pharm of Russia
October 15, 2014
- Parexel CEO Hails Rise of Partnership-Based Outsourcing in Japan
October 14, 2014
- Fujifilm’s Overseas Subsidiaries Develop High-Performance Mammalian Expression Platform
October 14, 2014
- Velcade Approved in US for Treatment-Naïve Mantle Cell Lymphoma: Takeda
October 14, 2014
- GSK to Market Authorized Generics through Aspen Japan Unit
October 10, 2014
- Kowa Loses Trademark Suit against Meiji Seika Pharma
October 10, 2014
- Ethical Drug Sales Down 7.2% in August, Switch to Generics Accelerated: Crecon Report
October 10, 2014
- AZ’s US Subsidiary Obtains Exclusive Rights to Shionogi’s Biologic Research Program
October 9, 2014
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…